Search the Library
NOTE: This is a new search platform (as of May 2026). If you do a search and don’t get the results you were expecting, please email us at ctnlib@uw.edu to let us know? (If possible, please share your exact search strategy. Thank you!)
Enter keywords and hit Enter (or click the magnifying glass) to search. You can then also select document type or subject/topic to narrow results further (or just use those for searching without a keyword). Results display below this search form.
Document types
Subjects
- CTN-#### format for protocols (CTN-0001, e.g.)
- “exact phrase” (if phrase is not found, it will return results that contain all terms
- word1 NOT word2
- word1 word2 (finds both words)
- Click title to access full-text
- “Show details” reveals abstract & other info
- Checkboxes select items for copy/pasting or printing
- Need help getting a copy of a journal article?
Email ctnlib@uw.edu
Search results
Dr. Korthuis reviewed the biological basis of medications for OUD, presented recent data on the effects of buprenorphine on patient outcomes, and introduced tools for integrating buprenorphine treatment into your current setting.
This webinar, sponsored by the Northwest ATTC and the Western States Node of the NIDA CTN, summarized what makes women’s treatment for substance use disorder (SUD) unique from men’s treatment and highlighted key issues when providing treatment to pregnant and parenting women with opioid use and other SUDs.
Peer recovery support services are supports provided across the service continuum by credentialed individuals in long-term recovery from alcohol or other drug-related problems. Peer recovery support specialists serving people following release from jails and prisons have a unique responsibility to support community reentry and adherence to community corrections requirements. They may also facilitate entry into treatment post-release and support engagement in recovery services in the months following incarceration. This webinar described the unique role of peer support specialists in the CDC-funded pilot project Reducing Overdose After Release from Incarceration (ROAR). The ROAR pilot combines provision of medication for opioid use disorder with support from Oregon Certified Recovery Mentors (CRMs) to reduce overdose risk among women released from prison.
In this session, John Kelly, PhD, ABPP of Harvard University discussed the fundamental causes of stigma in relation to substance use disorder, reviewed some of the paradoxical findings from the latest stigma research, and suggested how stigma might be more systematically addressed to enhance the clinical care and outcomes of individuals suffering from substance use disorder.
The goal of the National Institute of Drug Abuse (NIDA) Clinical Trials Network/Addiction Technology Transfer Center (ATTC) webinar series is to help scholars and clinicians in the addiction field stay abreast of cutting edge science. In this webinar, Keith Humphreys, PhD (Stanford University) explored the landscape of mutual help groups and the diverse mutual help groups that are available to patients. The clinical and cost effectiveness of group and 12-step programs were reviewed, as well as the clinical and policy implications of mutual help groups for promoting recovery from addiction.
This webinar provided an interactive learning experience for attendees to explore adolescent substance use and new paths for research. Presenter Niranjan Karnik, MD, PhD, director of the NIDA National Drug Abuse Treatment Clinical Trials Network (CTN) Great Lakes Node, reviewed recent data trends related to the prevalence of substance use among teens, described current treatment approaches, and talked about the pros and cons of social media and digital mental health interventions.
In this webinar co-hosted by the CTN Western States Node, Natania Crane, PhD, provides current information on research and treatment related to cannabis use and mental health, including recent changes in cannabis use, how the endocannabinoid system may regulate mental health symptoms, and what we currently know about cannabis use and mental health.
In this session, Drs. Rossom and Hooker discussed the design and implementation of Opioid Wizard, a clinical decision support tool embedded in the EHR for primary care clinicians and developed as part of NIDA Clinical Trials Network protocol CTN-0095. The goal of the tool is to help clinicians identify, screen, diagnose and treat opioid use disorder (OUD).
They also discussed one of the supplements to CTN-0095, which tested a training to reduce stigma towards people with OUD among primary care clinicians.
Related protocols: CTN-0095
In this session, Kathleen T. Brady, MD, PhD, of the Medical University of South Carolina, will discuss the NIDA Clinical Trials Network (CTN) study CTN-0108, “Transcranial Magnetic Stimulation for the Treatment of Methamphetamine/Cocaine Use Disorder,” a pilot study that aims to determine the feasibility, effectiveness, and safety for 20 sessions of repetitive transcranial magnetic stimulation (rTMS) versus sham in adults with a diagnosed methamphetamine or cocaine use disorder. Dr. Brady, co-Principal Investigator for CTN-0108, presented the rationale for the study, including the literature supporting the use of rTMS in stimulant use disorder, as well as the study methodology and preliminary results.
Related protocols: CTN-0108
This presentation from Noel Vest, PhD, Assistant Professor at Boston University School of Public Health, explored findings from a mixed-methods national study examining the structure, implementation, and impact of Collegiate Recovery Programs (CRPs) in the U.S. and Canada.
In this webinar, Erin Winstanley, PhD (University of Pittsburgh and West Virginia University, CTN Appalachian Node), described a NIDA Clinical Trials Network study, CTN-0135, examining clinician-reported challenges with initiating buprenorphine for people using fentanyl, including precipitated or prolonged withdrawal, patient reports that buprenorphine was ineffective, and patient preference for methadone. In response to these challenges, most clinicians surveyed reported modifying their standard induction protocols or patient counseling approaches. Clinicians treating larger patient volumes, seeing a high proportion of patients using fentanyl, or initiating treatment in non-inpatient settings were more likely to report difficulties starting patients on buprenorphine.
Related protocols: CTN-0135
Retention on buprenorphine for opioid use disorder is known to be poor across health systems, despite established mortality benefits of treatment, and little is known about how to counsel patients who want to stop using buprenorphine or who have to stop due to barriers to ongoing care.
This webinar will consider what the evidence from a prescription opioid registry developed by NIDA Clinical Trials Network study CTN-0084 suggests for individuals who discontinue buprenorphine, including whether there was a length-of-treatment exposure associated with improved outcomes. Implications for patient education and shared decision-making will be considered. Understanding the optimal length of treatment after which individuals can safely discontinue buprenorphine could help patients better understand what treatment might look like at the outset, supporting informed decision-making and potentially improving both treatment retention and outcomes.
Related protocols: CTN-0084
Evidence-based prevention interventions for young people have a shelf-life. When programs are revised and updated, it is unclear how much of the evidence carries over into the new edition. This presentation will review some of the challenges and opportunities associated with the recently released second edition of kiR as a case study. The updated version of kiR covers new types of drugs (e.g., vaping) and addresses co-occurring externalizing conditions (several forms of violence involvement). The original evidence was
gathered in Arizona, but kiR is being used nationwide and globally through culturally adapted versions. Additional research is needed to assess moderation of kiR program’s effects based on key participant characteristics and variations in implementation contexts across the US. The presentation will conclude by
exploring the possibility of assessing the feasibility and acceptability of the new version of kiR from multiple stakeholder viewpoints and to identify barriers and facilitators to its adoption and sustainment.
Stigma toward people with substance use disorders (SUD) remains a major barrier to care. This presentation described the methods, results, and implications of a scoping review completed by the CTN T&I SIG’s Implementation Strategies Workgroup to identify and describe implementation strategies used to reduce stigmatizing attitudes toward people with SUD in healthcare settings.
Culturally and contextually grounded preventive interventions can address upstream risk and protective factors to improve equity, but only if they are implemented in systems that serve underrepresented groups. This presentation from Cady Berkel, PhD (Arizona State University) shared findings a program of community based research conducted in partnership with multiple settings (e.g., pediatric primary care, family courts, corrections) to advance equitable access to evidence-based substance use prevention for adolescents and families. Dr. Berkel also discussed implementation science frameworks and designs to incorporate equity and accelerate the translation of research into practice.